Xavier Gitton

2.6k total citations · 1 hit paper
22 papers, 1.9k citations indexed

About

Xavier Gitton is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine and Rheumatology. According to data from OpenAlex, Xavier Gitton has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 11 papers in Cardiology and Cardiovascular Medicine and 6 papers in Rheumatology. Recurrent topics in Xavier Gitton's work include Inflammatory mediators and NSAID effects (13 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). Xavier Gitton is often cited by papers focused on Inflammatory mediators and NSAID effects (13 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). Xavier Gitton collaborates with scholars based in Switzerland, United States and United Kingdom. Xavier Gitton's co-authors include Gerhard Krammer, A. Widmer, Christopher J. Hawkey, Thomas J. Schnitzer, B. Mellein, Patrice Matchaba, Pierre Quartier, Jasmin Kuemmerle‐Deschner, É. Hachulla and Kieron Leslie and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Xavier Gitton

22 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

2009 627 citations Helen J. Lachmann, Isabelle Koné‐Paut et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xavier Gitton Switzerland	14	966	558	428	386	342	22	1.9k
Alberto Gimona United States	12	858 0.9×	506 0.9×	374 0.9×	63 0.2×	705 2.1×	23	2.3k
M.A. Barradas United Kingdom	23	202 0.2×	252 0.5×	460 1.1×	99 0.3×	395 1.2×	72	1.7k
Marta Brambilla Italy	24	104 0.1×	424 0.8×	362 0.8×	274 0.7×	222 0.6×	78	1.8k
Francesca Pizzolo Italy	29	111 0.1×	613 1.1×	444 1.0×	103 0.3×	780 2.3×	83	2.5k
Juana Vallés Spain	19	239 0.2×	244 0.4×	608 1.4×	222 0.6×	275 0.8×	65	1.7k
L B Safier United States	15	219 0.2×	301 0.5×	428 1.0×	211 0.5×	216 0.6×	25	1.7k
Keith Usiskin United States	24	661 0.7×	1.6k 2.8×	173 0.4×	224 0.6×	1.8k 5.3×	40	4.3k
Adam M. Smiles United States	28	77 0.1×	718 1.3×	282 0.7×	277 0.7×	547 1.6×	33	3.2k
Ohvanesse G. Ekindjian France	23	86 0.1×	378 0.7×	221 0.5×	213 0.6×	128 0.4×	83	1.6k
J. V. Lloyd Australia	29	201 0.2×	240 0.4×	441 1.0×	98 0.3×	351 1.0×	98	2.1k

Countries citing papers authored by Xavier Gitton

Since Specialization

Citations

This map shows the geographic impact of Xavier Gitton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Gitton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Gitton more than expected).

Fields of papers citing papers by Xavier Gitton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Gitton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Gitton. The network helps show where Xavier Gitton may publish in the future.

Co-authorship network of co-authors of Xavier Gitton

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Gitton. A scholar is included among the top collaborators of Xavier Gitton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Gitton. Xavier Gitton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lawrie, Allan, Kelly Chin, Y L Fong, et al.. (2024). Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER‐MRI studies. Pulmonary Circulation. 14(2). e12386–e12386. 2 indexed citations

Aras, Mandar A., Sean Abreau, Lakshmi Radhakrishnan, et al.. (2023). Electrocardiogram Detection of Pulmonary Hypertension Using Deep Learning. Journal of Cardiac Failure. 29(7). 1017–1028. 17 indexed citations

Alten, Rieke, Juan J. Gómez‐Reino, Patrick Durez, et al.. (2011). Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders. 12(1). 153–153. 114 indexed citations

Dougados, Maxime, Alan Moore, Shaohua Yu, & Xavier Gitton. (2011). Patient flow diagram. Figshare. 2 indexed citations

Lachmann, Helen J., Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner, et al.. (2009). Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine. 360(23). 2416–2425. 627 indexed citations breakdown →

Lachman, Herbert M., Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner, et al.. (2009). Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1b-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study. Journal of Allergy and Clinical Immunology. 123(3). 732–732. 1 indexed citations

Farkouh, Michael E., Freek W.A. Verheugt, Sean Ruland, et al.. (2008). A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen. Journal of Clinical Hypertension. 10(8). 592–602. 5 indexed citations

Daniels, Stephen, et al.. (2008). Efficacy and Tolerability of Lumiracoxib 200 mg Once Daily for Treatment of Primary Dysmenorrhea: Results from Two Randomized Controlled Trials. Journal of Women s Health. 17(3). 423–437. 16 indexed citations

Hawkey, Christopher J., Wilfred M. Weinstein, Walter Smalley, et al.. (2007). Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology. 133(1). 57–64. 17 indexed citations

10.

Dougados, Maxime, Alan Moore, Shaohua Yu, & Xavier Gitton. (2007). Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis Research & Therapy. 9(1). R11–R11. 39 indexed citations

11.

Hawkey, Christopher J., et al.. (2006). Gastrointestinal Tolerability of Lumiracoxib in Patients With Osteoarthritis and Rheumatoid Arthritis. Clinical Gastroenterology and Hepatology. 4(1). 57–66. 11 indexed citations

12.

Schnitzer, Thomas J., et al.. (2005). Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. Current Medical Research and Opinion. 21(1). 151–161. 17 indexed citations

13.

Matchaba, Patrice, Xavier Gitton, Gerhard Krammer, et al.. (2005). Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical Therapeutics. 27(8). 1196–1214. 44 indexed citations

14.

Schnitzer, Thomas J., Gerd R Burmester, Eduardo Mysler, et al.. (2004). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. The Lancet. 364(9435). 665–674. 493 indexed citations

15.

Hawkey, Christopher J., et al.. (2004). Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics. Alimentary Pharmacology & Therapeutics. 20(1). 51–63. 26 indexed citations

16.

Farkouh, Michael E., Howard S. Kirshner, Robert A. Harrington, et al.. (2004). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. The Lancet. 364(9435). 675–684. 364 indexed citations

17.

Schnitzer, Thomas J., Piet Geusens, Paul Hasler, et al.. (2004). Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis Care & Research. 51(4). 549–557. 46 indexed citations

18.

Hawkey, Christopher J., et al.. (2003). The gastrointestinal tolerability of a novel COX-2 selective inhibitor, lumiracoxb, in osteoarthritis patients: Pooled analysis. Gastroenterology. 124(4). A512–A512. 2 indexed citations

19.

Gitton, Xavier, et al.. (1994). Recognition of Leptospira interrogans antigens by vaccinated or infected dogs. Veterinary Microbiology. 41(1-2). 87–97. 18 indexed citations

20.

Gitton, Xavier, et al.. (1992). Immunoblotting study of the antigenic relationships among eight serogroups of Leptospira. Veterinary Microbiology. 32(3-4). 293–303. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact